156 related articles for article (PubMed ID: 21810511)
1. From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer.
de Gramont A; de Gramont A; Chibaudel B; Bachet JB; Larsen AK; Tournigand C; Louvet C; André T;
Semin Oncol; 2011 Aug; 38(4):521-32. PubMed ID: 21810511
[TBL] [Abstract][Full Text] [Related]
2. Stage II and stage III colon cancer: treatment advances and future directions.
Rousseau B; Chibaudel B; Bachet JB; Larsen AK; Tournigand C; Louvet C; André T; de Gramont A;
Cancer J; 2010; 16(3):202-9. PubMed ID: 20526097
[TBL] [Abstract][Full Text] [Related]
3. [Adjuvant and palliative anticancer treatment of colon carcinoma in 2004].
Medinger M; Steinbild S; Mross K
Praxis (Bern 1994); 2004 Sep; 93(40):1633-44. PubMed ID: 15495753
[TBL] [Abstract][Full Text] [Related]
4. Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer.
Bonetti A; Giuliani J; Muggia F
Anticancer Res; 2014 Jan; 34(1):423-34. PubMed ID: 24403498
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy in colon cancer--what, when and how?
Chau I; Cunningham D
Ann Oncol; 2006 Sep; 17(9):1347-59. PubMed ID: 16524974
[TBL] [Abstract][Full Text] [Related]
6. Why do targeted agents not work in the adjuvant setting in colon cancer?
Oyan B
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1337-45. PubMed ID: 23176621
[TBL] [Abstract][Full Text] [Related]
7. Targeted agents for adjuvant therapy of colon cancer.
Saif MW
Clin Colorectal Cancer; 2006 May; 6(1):46-51. PubMed ID: 16796791
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
9. Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer.
Abrams TA; Brightly R; Mao J; Kirkner G; Meyerhardt JA; Schrag D; Fuchs CS
J Clin Oncol; 2011 Aug; 29(24):3255-62. PubMed ID: 21768462
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
11. [Tumor targeting in colon cancer. Antibody therapy--a new adjuvant application].
Chirurg; 1995 Jul; 66(7 Suppl):1-4. PubMed ID: 9131058
[No Abstract] [Full Text] [Related]
12. [Adjuvant chemotherapy for colon cancer].
Dahl O
Tidsskr Nor Laegeforen; 2007 Nov; 127(23):3094-6. PubMed ID: 18049502
[TBL] [Abstract][Full Text] [Related]
13. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
14. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L
Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265
[TBL] [Abstract][Full Text] [Related]
15. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
16. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL
PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962
[TBL] [Abstract][Full Text] [Related]
17. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
18. An overview of approaches to adjuvant therapy for colorectal cancer in the United States.
Hobday TJ
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S11-8. PubMed ID: 15871761
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Lonardi S; Sobrero A; Rosati G; Di Bartolomeo M; Ronzoni M; Aprile G; Massida B; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Barni S; Zagonel V; Maiello E; Rulli E; Labianca R;
Ann Oncol; 2016 Nov; 27(11):2074-2081. PubMed ID: 27573560
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy for stage II and III colorectal cancer.
de Gramont A; Tournigand C; André T; Larsen AK; Louvet C
Semin Oncol; 2007 Apr; 34(2 Suppl 1):S37-40. PubMed ID: 17449351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
